엠폭스 백신 및 치료제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global monkeypox vaccine and treatment market size is expected to reach USD 304.23 Million in 2034 from USD 121.47 Million in 2025, growing at a CAGR of 10.74% during 2026-2034.The global monkeypox vaccine and treatment market has gained considerable attention due to the increasing incidence of monkeypox infections across various regions. The outbreak of the disease in several countries has highlighted the need for effective vaccines and antiviral treatments. As governments and healthcare organizations focus on controlling outbreaks, the demand for preventive vaccines and therapeutic drugs is increasing steadily. Pharmaceutical companies and research institutions are investing heavily in vaccine development and antiviral therapies to address the disease. Existing vaccines originally developed for smallpox have shown effectiveness against monkeypox, while new treatments are being explored to improve disease management. Public health initiatives and government procurement programs are also supporting the expansion of the market. In the future, the monkeypox vaccine and treatment market is expected to grow as global surveillance and preparedness for emerging infectious diseases increase. Rising awareness, improved diagnostic capabilities, and ongoing research into next-generation vaccines will contribute to market development. Continued collaboration between governments, healthcare organizations, and pharmaceutical companies will play a key role in shaping the market's future.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Product

• Vaccine (Jynneos/ Imvanex, Smallpox Vaccine, Others)
• Drugs (Tecovirimat, Brincidofovir, Cidofovir, Others)
• Vaccinia Immune Globulin (Vig)

By Gender

• Male
• Female
• Others

By Route Of Administration

• Oral
• Injectable
• By-End-Use
• Hospitals
• Specialty Clinics
• Others

COMPANIES PROFILED

• Bavarian Nordic, SIGA Technologies, Emergent BioSolutions, Tonix Pharmaceuticals, Chimerix, Johnson & Johnson, Sanofi, Merck & Co., Pfizer, Moderna, AstraZeneca, Roche, Takeda, BioNTech, Dynavax Technologies, Arbutus Biopharma, GeoVax Labs, NanoViricides, RedHill Biopharma, Inovio Pharmaceuticals

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL MONKEYPOX VACCINE AND TREATMENT MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Vaccine (Jynneos/ Imvanex, Smallpox Vaccine, Others) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Drugs (Tecovirimat, Brincidofovir, Cidofovir, Others) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Vaccinia Immune Globulin (Vig) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL MONKEYPOX VACCINE AND TREATMENT MARKET: BY GENDER 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Gender
• 5.2. Male Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Female Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL MONKEYPOX VACCINE AND TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL MONKEYPOX VACCINE AND TREATMENT MARKET: BY BY-END-USE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast By-end-use
• 7.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL MONKEYPOX VACCINE AND TREATMENT MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Product
  • 8.2.2 By Gender
  • 8.2.3 By Route Of Administration
  • 8.2.4 By By-end-use
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Product
  • 8.3.2 By Gender
  • 8.3.3 By Route Of Administration
  • 8.3.4 By By-end-use
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Spain
  • 8.3.10 Russia
  • 8.3.11 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Product
  • 8.4.2 By Gender
  • 8.4.3 By Route Of Administration
  • 8.4.4 By By-end-use
  • 8.4.5 China
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 India
  • 8.4.9 Australia
  • 8.4.10 South East Asia
  • 8.4.11 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Product
  • 8.5.2 By Gender
  • 8.5.3 By Route Of Administration
  • 8.5.4 By By-end-use
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Product
  • 8.6.2 By Gender
  • 8.6.3 By Route Of Administration
  • 8.6.4 By By-end-use
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL MONKEYPOX VACCINE AND TREATMENT INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Bavarian Nordic
  • 10.2.2 SIGA Technologies
  • 10.2.3 Emergent BioSolutions
  • 10.2.4 Tonix Pharmaceuticals
  • 10.2.5 Chimerix
  • 10.2.6 Johnson & Johnson
  • 10.2.7 Sanofi
  • 10.2.8 Merck & Co
  • 10.2.9 Pfizer
  • 10.2.10 Moderna
  • 10.2.11 AstraZeneca
  • 10.2.12 Roche
  • 10.2.13 Takeda
  • 10.2.14 BioNTech
  • 10.2.15 Dynavax Technologies
  • 10.2.16 Arbutus Biopharma
  • 10.2.17 GeoVax Labs
  • 10.2.18 NanoViricides
  • 10.2.19 RedHill Biopharma
  • 10.2.20 Inovio Pharmaceuticals